Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation

Table 1 Baseline characteristics

	‘DSA-positive’ group 1 (n = 54)	‘DSA-negative’ group 2 (n = 69)
Age
At LT (yr)	3.3 (1 mo-17 yr)	4.0 (1 mo-17.8 yr)
At follow-up (yr)	13.8 (2-23)	12.6 (1-24)
Gender
Female	n = 21	n = 35
Male	n = 33	n = 35
Main diagnosis
Biliary atresia	n = 20	n = 20
Alagille syndrome	n = 1	n = 8
Acute liver failure	n = 6	n = 4
Metabolic disorders1	n = 14	n = 26
Others2	n = 13	n = 11
Donor source
Ldlt	n = 9	n = 11
Ddlt	n = 45	n = 58
Full-graft	n = 8	n = 12
Split size	n = 30	n = 43
Reduced size	n = 7	n = 3
Cold ischemic time (min)	543.3 (122-949)	572.5 (145-943)
Relt	n = 22	n = 14
Graft loss due to
Cr	n = 23	n = 7
Alv	n = 7	n = 3
Thrombosis	n = 3	n = 3
Rond	n = 2	n = 0
Ssc	n = 2	n = 0
Time to DSA-testing
Years after current LT	9.75 (1-19)	7.98 (1-19)
Anti-HLA antibodies	n = 54	n = 32
Previous episodes
Of acute rejection	n = 12	n = 7
Of chronic rejection	n = 10	n = 3

¹Such as carbamoyl phosphate synthetase defects, ornithine transcarbamylase deficiency, primary hyperoxaluria, alpha1-antitrypsin-deficiency, glycogen storage disease, maple syrup urine disease, citrullinemia, Wilson disease, others.

²Such as idiopathic cirrhosis, autosomal recessive polycystic kidney disease, Crijgler-Najar syndrome, progressive familiar intrahepatic cholestasis, malignancies, vascular dysfunction, neonatal hepatitis, primary sclerosing cholangitis, autoimmune hepatitis.

LDLT: Living donor liver transplantation; DDLT: Dead donor liver transplantation; relt: Retransplantation; HLA: Human leucocyte antigen; DSA: Donor-specific antibodies; CR: Chronic rejection; ALV: Acute liver failure; ROND: Recurrence of native disease; SSC: Secondary sclerosing cholangitis.